Trials / Completed
CompletedNCT04093076
Dose-ranging Study: Safety, Tolerability and Immunogenicity of INO-4500 in Healthy Volunteers in Ghana
Dose-Ranging Study to Evaluate the Safety, Tolerability and Immunogenicity of INO-4500 in Combination With Electroporation in Healthy Volunteers in Ghana
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 220 (actual)
- Sponsor
- Inovio Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Accepted
Summary
This is a randomized, blinded, placebo-controlled trial to evaluate the safety, tolerability and immunological profile of INO-4500 administered by intradermal (ID) injection followed by electroporation (EP) using CELLECTRA™ 2000 device in healthy volunteers in Ghana.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | INO-4500 | INO-4500 will be administered ID on Day 0 and Week 4. |
| DEVICE | CELLECTRA™ 2000 | EP using the CELLECTRA™ 2000 device will be administered following ID drug administration. |
| DRUG | Placebo | Placebo will be administered ID on Day 0 and Week 4. |
Timeline
- Start date
- 2021-01-27
- Primary completion
- 2022-10-14
- Completion
- 2022-10-14
- First posted
- 2019-09-17
- Last updated
- 2022-11-21
Locations
1 site across 1 country: Ghana
Regulatory
- FDA-regulated drug study
- FDA-regulated device study
Source: ClinicalTrials.gov record NCT04093076. Inclusion in this directory is not an endorsement.